Italy’s Nutrilinea will formulate and distribute SlimBiome Medical, which also has medical device status, in boxes of 30 single sachet doses for sale across its network and the UK firm’s growing list of partners.
No financial details were given; however, Optibiotix said it wanted to “maximise the return” for both parties.
Chief executive Stephen O’Hara said: “We chose Nutrilinea due to their industry reputation, extensive European network and expertise in manufacture of high value food and medical products for Europe and the USA.
“We believe partners like Nutrilinea provide the best opportunity of building SlimBiome Medical into a global brand.
“We see CE marking and medical device registration as an exciting extension of SlimBiome from food products into high value medical products in consumer healthcare and pharmaceutical markets which we hope will contribute substantive revenues to OptiBiotix's growth in the months and years ahead."